ABBV vs NVS
ABBV: A global biopharmaceutical leader focused on developing innovative medicines for complex diseases across immunology, oncology, neuroscience, and aesthetics. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | ABBV | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $256.91 | $156.11 | |
| Market cap as of 2026-08-01 | $453.9B | $232.1B | |
| P/E as of 2026-08-01 | 122.88 | 22.48 | NVS lower |
| PEG as of 2026-08-01 | 6.59 | 3.66 | NVS lower |
| Net margin as of 2026-08-01 | +5.8% | +22.5% | NVS higher |
| Gross margin as of 2026-08-01 | +72.0% | +75.0% | NVS higher |
| Operating margin as of 2026-08-01 | +24.4% | +29.9% | NVS higher |
| ROE as of 2026-08-01 | +95.6% | +29.9% | ABBV higher |
| ROA as of 2026-08-01 | +2.7% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-01 | 49.22 | 1.18 | NVS lower |
| Revenue growth (YoY) as of 2026-08-01 | +9.5% | +3.3% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | n/a | |
| Dividend yield as of 2026-08-01 | +2.7% | +2.9% | NVS higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-01 | 0.27 | 1.17 | |
| 1-year return as of 2026-07-27 close | +35.0% | +32.6% | ABBV higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.